Abstract: A process for purifying pentostatin from a crude fermentation beer comprising the steps of 1) applying the fermentation beer to a strong cation exchange resin; 2) eluting with ammonium hydroxide; 3) concentrating the eluate; 4) applying the concentrated eluate to a strongly basic anion exchange resin charged with borate ion; 5) eluting with water; 6) applying this eluate to styrene-divinylbenzene beads prewashed with ethanol; 7) eluting the beads with water; and 8) recrysllyzing the pentostatin from water and methanol to yield a product that is greater than 99.7% pure.

Abstract: A purified isolate of an actinomycete identified as ATCC 39366 is capable of producing the anti-microbial compound CL-1957B which also exhibits antitumor properties.The antimicrobial compound CL-1957B is produced by cultivating isolate ATCC 39366 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial quantity of the CL-1957B compound is produced, and subsequently isolating the compound.The antibiotic compound CL-1957B, its pharmaceutically acceptable salts, the pharmaceutical compositions comprising this substance together with a pharmaceutically acceptable carrier is also disclosed, as are methods of treating microbial infections and tumors in mammals, employing these pharmaceutical compositions.

Abstract: A purified isolate of an actinomycete identified as ATCC 39366 is capable of producing the anti-microbial compound CL-1957A which also exhibits antitumor properties.The antimicrobial compound CL-1957A is produced by cultivating isolate ATCC 39366 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial quantity of the CL-1957A compound is produced, and subsequently isolating the CL-1957A compound.The antibiotic compound CL-1957A and pharmaceutical compositions comprising this substance together with a pharmaceutically acceptable carrier is also disclosed, as are methods of treating microbial infections and tumors in mammals, employing these pharmaceutical compositions.

Abstract: A purified isolate of an actinomycete identified as ATCC 39366 is capable of producing the antimicrobial compound CL-1957E which also exhibits antitumor properties.The antimicrobial compound CL-1957E is produced by cultivating isolate ATCC 39366 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantially quantity of the CL-1957E compound is produced, and subsequently isolating the CL-1957E compound.The antibiotic compound CL-1957E and pharmaceutical compositions comprising this substance together with a pharmaceutically acceptable carrier is also disclosed, as are methods of treating microbial infections and tumors in mammals, employing these pharmaceutical compositions.

Abstract: 2'-Chloropentostatin is a potent inhibitor of the enzyme adenosine deaminase and possesses utility as an agent for potentiating the activity of antiviral agents for the treatment of DNA viruses which agents contain an adenine moiety, such as 9-(beta-D-arabinosyl)adenine. A pure strain of actinomycete, designated ATCC 39365 which is capable of producing 2'-chloropentostatin, a method of producing 2'-chloropentostatin by aerobic fermentation, and pharmaceutical compositions including 2'-chloropentostatin are also disclosed.

Abstract: A purified isolate of an actinomycete identified as ATCC 39366 is capable of producing the antimicrobial compound CL-1957D.The antimicrobial compound CL-1957D is produced by cultivating isolate ATCC 39366 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial quantity of the CL-1957D compound is produced, and subsequently isolating the CL-1957D compound.The antibiotic compound CL-1957D and pharmaceutical compositions comprising this substance together with a pharmaceutically acceptable carrier is also disclosed, as are methods of treating microbial infections in mammals, employing these pharmaceutical compositions.

Abstract: Novel pyranone compounds and related compounds, methods of preparing the compounds, and their use as cytotoxic and/or antileukemic agents or precursors, are provided.

Abstract: CL-1577-B.sub.4 compound is derived by the solvolysis under anhydrous conditions of either CL-1577A compound of CL-1577B compound, obtained from the fermentative action of a purified strain of Actinomycete designated ATCC 39363 under aerobic conditions.CL-1577-B.sub.4 compound is a potent antimicrobial agent, possessing activity against a number of gram-positive and gram-negative bacteria, yeasts, and fungi. In addition, the compound exhibits in vivo activity against the P388 murine leukemia cell line and in vitro activity against the L1210 murine leukemia cell line.A method of making the compound as well as pharmaceutical compositions and methods for their use are also disclosed.

Abstract: Acids, esters, imine acids, imine esters, and imine amides derived from 6-formyl-4,7,9-trihydroxy-1-phenazinecarboxylic acid, methyl ester and from 6-formyl-4,7,9-trihydroxy-8-methyl-1-phenazinecarboxylic acid, methyl ester demonstrate antimicrobial and antineoplastic activity.A purified strain of Streptomyces galanosa, NRRL 15738, is capable of producing 6-formyl-4,7,9-trihydroxy-8-methyl-1-phenazinecarboxylic acid, methyl ester in isolable quantities from a fermentation broth containing assimilable sources of carbon and nitrogen.

Abstract: CL-1577-B.sub.4 compound is derived by the solvolysis under anhydrous conditions of either CL-1577A compound or CL-1577B compound, obtained from the fermentative action of a purified strain of Actinomycete designated ATCC 39363 under aerobic conditions.CL-1577-B.sub.4 compound is a potent antimicrobial agent, possessing activity against a number of gram-positive and gram-negative bacteria, yeasts, and fungi. In addition, the compound exhibits in vivo activity against the P388 murine leukemia cell line and in vitro activity against the L1210 murine leukemia cell line.A method of making the compound as well as pharmaceutical compositions and methods for their use are also disclosed.

Abstract: Novel phosphorus containing antibiotic compounds that are antitumor agents designated CL 1565-A, CL 1565-B, CL 1565-T and their salts, a process for the production and the method of using said compounds, and pharmaceutical compositions containing various salts of the compounds of the invention alone or in combination with other antitumor agents in the treatment of microbial infections and neoplastic diseases, are provided.

Abstract: A strain of actinomycete, NRRL 15758, is capable of producing the CL-1724 complex of compounds under conditions of aerobic fermentation in the presence of assimilable sources of carbon and nitrogen. The compound CL-1724B-2 exhibiting antimicrobial and antitumor activity, is claimed together with pharmaceutical compositions and methods of treating microbial infections and tumors in mammals employing these pharmaceutical compositions.

Abstract: A purified isolate of an actinomycete identified as ATCC 39364 is capable of producing the antimicrobial/antitumor compound 2-amino-1,9-dihydro-6H-purine-6-one-7-oxide, commonly known as guanine-N.sup.7 -oxide.Guanine-N.sup.7 -oxide is produced by cultivating isolate ATCC 39364 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial amount of the compound is produced and thereafter isolating the compound.The antibiotic/antitumor compound guanine-N.sup.7 -oxide and pharmaceutical compositions comprising this compound or one of its pharmaceutically acceptable salts together with a pharmaceutically acceptable carrier are also disclosed as is a method of treating microbial infections in a mammal or of treating tumors in a mammal.

Abstract: Compounds CL-1577D and CL-1577E are prepared by cultivation of a purified isolate of Actinomycete designated ATCC 39363 in a culture medium having assimilable sources of carbon and nitrogen. The compounds are effective antimicrobial agents and possess cytotoxic activity against L1210 murine leukemia cells and P388 murine leukemia cells.

Abstract: A purified isolate of an actinomycete identified as ATCC 39363 is capable of producing a complex of sulfur-containing antibiotic compounds having activity against transplanted tumors.Antibiotic compounds CL-1577A and CL-1577B and their closely related congeners are produced by cultivating isolate ATCC 39363 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial quantity of the CL-1577 complex is produced, and subsequently isolating the complex or one or more of the compounds.The antibiotic compounds CL-1577A, CL-1577B, their congeners, and pharmaceutical compositions comprising these substances together with a suitable carrier are also disclosed.

Abstract: The present invention relates to roridin E-2 which is represented by Formula I and a process for the production of said compound.

Abstract: The present invention relates to the novel trichothecenes, 12'-hydroxyverrucarin J and iso-satratoxin H, and a fermentation process for the production of said compounds.The invention also relates to pharmaceutical compositions comprising said compounds and methods for using said compositions.

Abstract: The present invention relates to a novel trichothecene antibiotic, roridin L-2, and a process for the production and the method of using said compound.